Description

Sofosvel is the global first generic oral tablet for pan-genotypic Chronic Hepatitis C treatment. This combination (Sofosbuvir 400 mg + Valpatasvir 100 mg) drug has been approved by US FDA European Commission for treatment of patients with all genotypic Chronic Hepatitis C virus infection. Sofosvel is used without cirrhosis or with compensated cirrhosis, and patients with advanced cirrhosis (Decompensated). Therapeutic indications: Sofosvel is indicated for the treatment of adult patients with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infections With or without cirrhosis or with compensated cirrhosis With decompensated cirrhosis for use in combination with Ribavirin Specification: Brand Name : Sofosvel Generic Name : Sofosbuvir 400mg + Velpatasvir 100 mg Formulation : Solid dosage form(Tablet) Available pack size : 1×6’s Strengths : Sofobuvir 400mg+ Velpatasvir 100m